Results 51 to 60 of about 85,257 (242)

Efferent therapy in the first-line drug treatment of metastatic colorectal cancer

Медицинский совет, 2018
The aim of this study is to analyse the efficacy of efferent therapy (hemosorption) as part of drug treatment in patients with metastatic colorectal cancer (mCRC) based on the use of standard first-line chemotherapy combined with the bevacizumab ...
Z. S. Kotova, T. Yu. Semiglazova, I. A. Baldueva, D. H. Latipova, D. O. Yurlov, V. V. Semiglazov, G. M. Teletaeva, A. V. Novik, A. I. Semenova, S. A. Protsenko   +9 more
doaj   +1 more source

Recent Advances in Functional Liver Volumetry: Emphasis on 99mTc‐GSA SPECT/CT Fusion Imaging

Annals of Gastroenterological Surgery, EarlyView.
Functional liver volumetry enables more accurate assessment of the future liver remnant by integrating anatomical and functional information, improving risk stratification before major hepatectomy. Among available techniques, 99mTc‐GSA SPECT/CT fusion imaging enables precise regional functional assessment and more reliable prediction of post ...
Toru Beppu, Toshiro Masuda, Yasunori Nagayama, Hidetoshi Nitta, Hiromitsu Hayashi   +4 more
wiley   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Bevacizumab in maintenance therapy for ovarian cancer patients

Южно-Российский онкологический журнал, 2020
Ovarian cancer is one of the most common cancers in women. Growth and extension of the tumor are associated with active neoangiogenesis regulated by vascular endothelial growth factor (VEGF).
L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, E. V. Verenikina, S. N. Kabanov, Ya. V. Svetitskaya, N. Yu. Samaneva, N. M. Tikhanovskaya, K. A. Novoselova, O. G. Selezneva, A. V. Tishina   +10 more
doaj   +1 more source

Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations

American Journal of Hematology, EarlyView.
Targeted antiangiogenic therapy with systemic bevacizumab for bleeding from acquired GI VMs was found to be safe and effective for chronic and severe bleeding from acquired vascular malformations due to idiopathic angiodysplasia, chronic liver disease, and deficiencies of von Willebrand factor, in a patient population comprised mostly of heavily ...
Nardeen E. Ayad, Jacob R. Anderson, Bimalangshu Dey, Rebecca Karp Leaf, Andrew B. Song, Hanny Al‐Samkari   +5 more
wiley   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data

Tumor Biology, 2017
To evaluate the association between severe pulmonary embolism events and bevacizumab, we conducted the first meta-analysis evaluating the incidence and risk of pulmonary embolism associated with bevacizumab-based therapy.
Meidan Liu, Yayuan Zheng, Zuguang Chen, Yumiao Qiu, Zhanchun Pan, Zitao Cai, Yapeng Shi, Junfen Cheng, Weimin Yao   +8 more
doaj   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy

Physics and Imaging in Radiation Oncology, 2018
Stereotactic body radiotherapy (SBRT) and bevacizumab are used in the treatment of colorectal liver metastases. This study prospectively evaluated changes in perfusion of liver metastases in seven patients treated with both bevacizumab and SBRT ...
Jay S. Detsky, Laurent Milot, Yoo-Joung Ko, Pablo Munoz-Schuffenegger, William Chu, Gregory Czarnota, Hans T. Chung   +6 more
doaj   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source